Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 10/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271772 | 0.93 | HPGDS (0.43) | PAK1HPGDSGRIN2BKCNH2CYP2D6 | |
| SCHEMBL8271780 | 0.91 | HPGDS (0.43) | PAK1HPGDSGRIN2BKCNH2CYP2D6 | |
| SCHEMBL14349445 | 0.91 | PAK1 (0.45) | PAK1HPGDSGRIN2BKCNH2CYP2D6 | |
| SCHEMBL14349399 | 0.91 | PAK1 (0.45) | PAK1HPGDSGRIN2BKCNH2CYP2D6 | |
| SCHEMBL18331855 | 0.91 | HPGDS (0.43) | PAK1HPGDSGRIN2BKCNH2CYP2D6 | |
| SCHEMBL5660340 | 0.91 | LMNA (0.45) | PAK1HPGDSGRIN2BKCNH2CYP1A2 | |
| SCHEMBL8271774 | 0.91 | HPGDS (0.41) | PAK1HPGDSGRIN2BKCNH2CYP1A2 | |
| SCHEMBL8271777 | 0.91 | PAK1 (0.48) | PAK1HPGDSGRIN2BKCNH2CYP2D6 | |
| SCHEMBL14349479 | 0.89 | GRIN2B (0.51) | PAK1HPGDSGRIN2BKCNH2CYP2D6 | |
| SCHEMBL14349427 | 0.88 | GRIN2B (0.40) | PAK1HPGDSGRIN2BKCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838530-B1 | METHODS FOR TREATING PARKINSON'S DISEASE | UCB BIOPHARMA SPRL (BE) | 2017-04-05 | — | — | EP | disclosed |
| US-20160367560-A1 | Methods for Treating Parkinson's Disease | UCB PHARMA, S.A. (BE) | 2016-12-22 | — | — | US | disclosed |
| US-9387212-B2 | Methods for treating Parkinson's disease | UCB BIOPHARMA SPRL (BE) | 2016-07-12 | — | — | US | disclosed |
| US-9387212-B2 | Methods for treating Parkinson's disease | UCB BIOPHARMA SPRL (BE) | 2016-07-12 | — | — | US | disclosed |
| US-20150157638-A1 | Methods for Treating Parkinson's Disease | UCB BIOPHARMA SPRL (BE) | 2015-06-11 | — | — | US | disclosed |
| US-20150157638-A1 | Methods for Treating Parkinson's Disease | UCB BIOPHARMA SPRL (BE) | 2015-06-11 | — | — | US | disclosed |
| EP-2838530-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | UCB Pharma, S.A. (BE) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013156614-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | UCB PHARMA S.A. (BE) | 2013-10-24 | — | — | WO | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| WO-2006017409-A2 | 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | GRIN2B, GRIN2A, GRIN1 | PAK1 2143/4885HPGDS 1733/4885GRIN2B 1/4885 |
| US-20150157638-A1 | Methods for Treating Parkinson's Disease | ADORA2A, GRIN2A, GRIN3A | PAK1 1830/4885HPGDS 2591/4885GRIN2B 5/4885 |
| US-20160367560-A1 | Methods for Treating Parkinson's Disease | ADORA2A, GRIN2A, GRIN3A | PAK1 1830/4885HPGDS 2591/4885GRIN2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.